Oragenics, Intrexon in deal to develop genetically modified probiotics

Oragenics (OGEN +3.7%) and Intrexon (XON +0.5%) establish an Exclusive Channel Collaboration for the development and commercialization of "genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus."

The companies intends to initially focus on a treatment for oral lesions associated with Behcet's. (PR)

Previous: XON, OGEN announce results from lantibiotics testing

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs